After today's positive trading update, Executive Chairman Jay Lecoque of SourceBio International takes me through the details:
Tremendous underlying demand being experienced in the Cellular Pathology operation Start
Integration & synergies from the LDPath acquisition 03:24
Planned capacity expansion 05:16
Introduction of AI 06:06
Genomics division & opportunity in Precision Medicine. 08:09
Stability Storage 10:19
Repurposing Covid testing resource & equipment 11:22
Possible future M&A 12:30
SBI’s overall outlook for 2022. 13:02
SourceBio International - Q&A with Executive Chairman Jay Lecoque
Jun 15, 2022Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.